Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer
<p>Abstract</p> <p>Background</p> <p>Interleukin-13 Receptor α2 (IL-13Rα2) is a tumor-associated antigen and target for cancer therapy. Since IL-13Rα2 is heterogeneously overexpressed in a variety of human cancers, it would be highly desirable to uniformly upregulate IL...
Main Authors: | Puri Raj K, Joshi Bharat H, Fujisawa Toshio |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-04-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://www.translational-medicine.com/content/9/1/37 |
Similar Items
-
IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer
by: Toshio Fujisawa, et al.
Published: (2021-06-01) -
Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer
by: Jingwei Shi, et al.
Published: (2021-03-01) -
Upregulation of p75NTR by Histone Deacetylase Inhibitors Sensitizes Human Neuroblastoma Cells to Targeted Immunotoxin-Induced Apoptosis
by: Simona Dedoni, et al.
Published: (2022-03-01) -
A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma
by: Toshio Fujisawa, et al.
Published: (2020-05-01) -
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
by: Brendan L. Hagerty, et al.
Published: (2020-06-01)